Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Edema | 5 | 2022 | 99 | 1.970 |
Why?
|
| Thermotolerance | 2 | 2024 | 5 | 1.820 |
Why?
|
| Diabetic Retinopathy | 5 | 2022 | 169 | 1.810 |
Why?
|
| Visual Acuity | 7 | 2022 | 869 | 1.390 |
Why?
|
| Climate Change | 3 | 2024 | 63 | 1.180 |
Why?
|
| Chiroptera | 2 | 2025 | 17 | 1.150 |
Why?
|
| Ranibizumab | 3 | 2019 | 76 | 1.140 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2021 | 221 | 1.050 |
Why?
|
| Starvation | 2 | 2024 | 18 | 1.030 |
Why?
|
| Disease Reservoirs | 2 | 2025 | 37 | 0.980 |
Why?
|
| One Health | 1 | 2024 | 3 | 0.920 |
Why?
|
| Ophthalmic Solutions | 1 | 2024 | 94 | 0.860 |
Why?
|
| Anesthetics, Local | 1 | 2024 | 95 | 0.810 |
Why?
|
| Anatomy | 1 | 2020 | 11 | 0.700 |
Why?
|
| Deep Brain Stimulation | 9 | 2021 | 427 | 0.690 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2019 | 449 | 0.680 |
Why?
|
| Status Epilepticus | 3 | 2020 | 154 | 0.670 |
Why?
|
| Macular Degeneration | 1 | 2021 | 128 | 0.650 |
Why?
|
| Phenytoin | 2 | 2020 | 64 | 0.650 |
Why?
|
| Bees | 3 | 2024 | 53 | 0.620 |
Why?
|
| Anticonvulsants | 3 | 2020 | 392 | 0.620 |
Why?
|
| Valproic Acid | 2 | 2020 | 168 | 0.620 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 169 | 0.590 |
Why?
|
| Laser Coagulation | 1 | 2019 | 132 | 0.580 |
Why?
|
| Dystonic Disorders | 4 | 2022 | 93 | 0.530 |
Why?
|
| Intravitreal Injections | 5 | 2022 | 156 | 0.520 |
Why?
|
| Students, Medical | 1 | 2020 | 367 | 0.490 |
Why?
|
| Dystonia | 4 | 2022 | 175 | 0.470 |
Why?
|
| Hot Temperature | 2 | 2024 | 145 | 0.430 |
Why?
|
| Globus Pallidus | 4 | 2021 | 69 | 0.420 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 934 | 0.420 |
Why?
|
| Double-Blind Method | 7 | 2020 | 1667 | 0.320 |
Why?
|
| Tomography, Optical Coherence | 5 | 2019 | 586 | 0.270 |
Why?
|
| Informed Consent | 2 | 2024 | 345 | 0.270 |
Why?
|
| Humans | 36 | 2025 | 133935 | 0.270 |
Why?
|
| Child, Preschool | 13 | 2024 | 14802 | 0.240 |
Why?
|
| Ecology | 1 | 2024 | 16 | 0.230 |
Why?
|
| Disease Resistance | 1 | 2025 | 28 | 0.230 |
Why?
|
| Desiccation | 1 | 2024 | 46 | 0.230 |
Why?
|
| Adolescent | 16 | 2024 | 20536 | 0.230 |
Why?
|
| Virology | 1 | 2024 | 36 | 0.230 |
Why?
|
| Movement Disorders | 2 | 2022 | 226 | 0.230 |
Why?
|
| Propoxycaine | 1 | 2024 | 3 | 0.230 |
Why?
|
| Acclimatization | 1 | 2024 | 24 | 0.220 |
Why?
|
| Immune Tolerance | 1 | 2025 | 158 | 0.220 |
Why?
|
| Animals | 6 | 2025 | 36387 | 0.220 |
Why?
|
| Adaptive Immunity | 1 | 2024 | 97 | 0.220 |
Why?
|
| Male | 24 | 2024 | 65904 | 0.210 |
Why?
|
| Body Temperature Regulation | 1 | 2024 | 50 | 0.210 |
Why?
|
| Single-Blind Method | 1 | 2024 | 251 | 0.210 |
Why?
|
| Female | 25 | 2024 | 71684 | 0.210 |
Why?
|
| Congresses as Topic | 1 | 2024 | 187 | 0.210 |
Why?
|
| Treatment Outcome | 11 | 2021 | 13010 | 0.200 |
Why?
|
| Child | 16 | 2024 | 25742 | 0.200 |
Why?
|
| Adaptation, Physiological | 1 | 2025 | 291 | 0.200 |
Why?
|
| Cold-Shock Response | 1 | 2022 | 4 | 0.200 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2022 | 6 | 0.190 |
Why?
|
| Myoclonus | 1 | 2022 | 34 | 0.190 |
Why?
|
| Fluocinolone Acetonide | 1 | 2022 | 7 | 0.190 |
Why?
|
| Bevacizumab | 2 | 2019 | 80 | 0.190 |
Why?
|
| Drug Implants | 1 | 2022 | 44 | 0.190 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2021 | 2 | 0.190 |
Why?
|
| Macula Lutea | 2 | 2019 | 51 | 0.190 |
Why?
|
| Virus Diseases | 1 | 2024 | 289 | 0.190 |
Why?
|
| Genome | 1 | 2025 | 526 | 0.190 |
Why?
|
| Lymphedema | 1 | 2021 | 21 | 0.190 |
Why?
|
| Temperature | 1 | 2022 | 330 | 0.190 |
Why?
|
| Emergency Medical Services | 2 | 2024 | 413 | 0.180 |
Why?
|
| Lesch-Nyhan Syndrome | 1 | 2021 | 11 | 0.180 |
Why?
|
| Sports | 1 | 2022 | 69 | 0.180 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 2020 | 3 | 0.180 |
Why?
|
| Young Adult | 12 | 2021 | 9890 | 0.180 |
Why?
|
| Steroids | 1 | 2022 | 210 | 0.170 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 286 | 0.170 |
Why?
|
| Cadaver | 1 | 2020 | 141 | 0.170 |
Why?
|
| Middle Aged | 11 | 2024 | 29409 | 0.170 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2020 | 16 | 0.170 |
Why?
|
| Population Groups | 1 | 2020 | 31 | 0.170 |
Why?
|
| Adolescent Behavior | 1 | 2022 | 179 | 0.160 |
Why?
|
| Emergency Medicine | 1 | 2022 | 160 | 0.160 |
Why?
|
| Gonorrhea | 1 | 2020 | 40 | 0.160 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 175 | 0.160 |
Why?
|
| Fibrinolysin | 1 | 2019 | 13 | 0.160 |
Why?
|
| Vitreous Detachment | 1 | 2019 | 15 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2022 | 406 | 0.150 |
Why?
|
| Visual Field Tests | 1 | 2019 | 55 | 0.150 |
Why?
|
| Retinal Perforations | 1 | 2019 | 27 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2021 | 5183 | 0.150 |
Why?
|
| Seizures | 1 | 2024 | 889 | 0.150 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2018 | 21 | 0.150 |
Why?
|
| Hyperkinesis | 1 | 2018 | 27 | 0.150 |
Why?
|
| Educational Measurement | 1 | 2020 | 338 | 0.140 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 153 | 0.140 |
Why?
|
| Visual Fields | 1 | 2019 | 151 | 0.140 |
Why?
|
| Phenotype | 3 | 2022 | 4548 | 0.130 |
Why?
|
| Electric Power Supplies | 1 | 2017 | 19 | 0.130 |
Why?
|
| Adult | 14 | 2024 | 31950 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 375 | 0.130 |
Why?
|
| Infant | 5 | 2024 | 13163 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2024 | 734 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 165 | 0.130 |
Why?
|
| Cerebellar Ataxia | 1 | 2016 | 67 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1069 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 776 | 0.120 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2014 | 2 | 0.120 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2014 | 7 | 0.120 |
Why?
|
| Melanosis | 1 | 2014 | 10 | 0.120 |
Why?
|
| Nevus, Pigmented | 1 | 2014 | 34 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2019 | 833 | 0.110 |
Why?
|
| Efferent Pathways | 1 | 2014 | 9 | 0.110 |
Why?
|
| Diazepam | 1 | 2014 | 22 | 0.110 |
Why?
|
| Lorazepam | 1 | 2014 | 12 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 290 | 0.110 |
Why?
|
| Disclosure | 1 | 2014 | 154 | 0.110 |
Why?
|
| Time Factors | 3 | 2019 | 6590 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1735 | 0.090 |
Why?
|
| Exome | 1 | 2016 | 1067 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2022 | 1250 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1022 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 481 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 960 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2022 | 6663 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5511 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1833 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2420 | 0.080 |
Why?
|
| Neuronavigation | 1 | 2009 | 10 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 3851 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 1206 | 0.080 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 198 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2019 | 110 | 0.080 |
Why?
|
| Postoperative Hemorrhage | 1 | 2009 | 84 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 135 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2019 | 264 | 0.080 |
Why?
|
| Age Distribution | 1 | 2020 | 444 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2763 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2019 | 102 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 570 | 0.070 |
Why?
|
| Hypotension | 1 | 2019 | 191 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 6297 | 0.070 |
Why?
|
| Aged | 6 | 2020 | 21745 | 0.060 |
Why?
|
| Ubiquitins | 1 | 2025 | 44 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1217 | 0.060 |
Why?
|
| Voice Training | 1 | 2024 | 7 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2025 | 168 | 0.050 |
Why?
|
| Midazolam | 1 | 2024 | 47 | 0.050 |
Why?
|
| Speech Therapy | 1 | 2024 | 15 | 0.050 |
Why?
|
| Dysarthria | 1 | 2024 | 25 | 0.050 |
Why?
|
| Valsartan | 1 | 2023 | 23 | 0.050 |
Why?
|
| Species Specificity | 1 | 2025 | 570 | 0.050 |
Why?
|
| Spain | 1 | 2023 | 65 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 7211 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2023 | 64 | 0.050 |
Why?
|
| Public Opinion | 1 | 2024 | 60 | 0.050 |
Why?
|
| Age Factors | 1 | 2020 | 2979 | 0.050 |
Why?
|
| Electrodes, Implanted | 2 | 2017 | 169 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2023 | 283 | 0.050 |
Why?
|
| Sarcoglycans | 1 | 2022 | 8 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 138 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 5 | 0.050 |
Why?
|
| Phylogeny | 1 | 2025 | 784 | 0.050 |
Why?
|
| Cell Separation | 1 | 2022 | 234 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2021 | 86 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 530 | 0.040 |
Why?
|
| Pantothenic Acid | 1 | 2020 | 7 | 0.040 |
Why?
|
| Laryngeal Diseases | 1 | 2020 | 32 | 0.040 |
Why?
|
| Saliva | 1 | 2021 | 132 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 148 | 0.040 |
Why?
|
| United States | 3 | 2024 | 11686 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 46 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 132 | 0.040 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2020 | 46 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 94 | 0.040 |
Why?
|
| Plasma Kallikrein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 62 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2022 | 317 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2022 | 836 | 0.040 |
Why?
|
| Students | 1 | 2022 | 261 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 562 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2019 | 31 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 384 | 0.040 |
Why?
|
| Cytokines | 1 | 2025 | 1396 | 0.040 |
Why?
|
| Vitreous Body | 1 | 2019 | 107 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 248 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 17487 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2021 | 507 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 430 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 332 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2020 | 701 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 664 | 0.030 |
Why?
|
| Peroxisomal Multifunctional Protein-2 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Genomics | 1 | 2025 | 1675 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 104 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2020 | 930 | 0.030 |
Why?
|
| Exercise | 1 | 2022 | 876 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 801 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 635 | 0.030 |
Why?
|
| Third-Party Consent | 1 | 2014 | 28 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2242 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 69 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 432 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 215 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1150 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 211 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3990 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 589 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3740 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2654 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 419 | 0.020 |
Why?
|
| Differential Threshold | 1 | 2011 | 11 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1066 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 177 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 183 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2011 | 112 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 571 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2011 | 81 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2143 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 173 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 454 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 746 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1471 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2009 | 68 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 136 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2011 | 288 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2014 | 556 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 175 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 261 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2807 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2009 | 284 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 2161 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1494 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1046 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 396 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3475 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 18909 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 3639 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2295 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8591 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 3076 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 3221 | 0.010 |
Why?
|